CoChat

Effects of Ferroportin-Mediated Iron Depletion in Cells Representative of Different Histological Subtypes of Prostate Cancer

Open access
Deng, Zhiyong, Manz, David H., Torti, Suzy V., Torti, Frank M. · 2019 · Antioxidants & Redox Signaling
Cited by 47

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

AIMS: Ferroportin (FPN) is an iron exporter that plays an important role in cellular and systemic iron metabolism. Our previous work has demonstrated that FPN is decreased in prostate tumors. We sought to identify the molecular pathways regulated by FPN in prostate cancer cells. RESULTS: We show that overexpression of FPN induces profound effects in cells representative of multiple histological subtypes of prostate cancer by activating different but converging pathways. Induction of FPN induces autophagy and activates the transcription factors tumor protein 53 (p53) and Kruppel-like factor 6 (KLF6) and their common downstream target, cyclin-dependent kinase inhibitor 1A (p21). FPN also induces cell cycle arrest and stress-induced DNA-damage genes. Effects of FPN are attributable to its effects on intracellular iron and can be reproduced with iron chelators. Importantly, expression of FPN not only inhibits proliferation of all prostate cancer cells studied but also reduces growth of tumors derived from castrate-resistant adenocarcinoma C4-2 cells in vivo. INNOVATION: We use a novel model of FPN expression to interrogate molecular pathways triggered by iron depletion in prostate cancer cells. Since prostate cancer encompasses different subtypes with a highly variable clinical course, we further explore how histopathological subtype influences the response to iron depletion. We demonstrate that prostate cancer cells that derive from different histopathological subtypes activate converging pathways in response to FPN-mediated iron depletion. Activation of these pathways is sufficient to significantly reduce the growth of treatment-refractory C4-2 prostate tumors in vivo. CONCLUSIONS: Our results may explain why FPN is dramatically suppressed in cancer cells, and they suggest that FPN agonists may be beneficial in the treatment of prostate cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1089/ars.2017.7023

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 57

  1. 10.1016/j.febslet.2006.10.077 · DOI
  2. 10.1021/acs.jcim.6b00450 · DOI
  3. 10.1158/0008-5472.CAN-03-2818 · DOI · Paper page
  4. 10.1016/j.cmet.2013.06.019 · DOI · Paper page
  5. 10.1038/nrc3711 · DOI · Paper page
  6. 10.1586/17474086.2016.1124757 · DOI · Paper page
  7. 10.3322/canjclin.39.6.376 · doi:10.3322/canjclin.39.6.376
  8. 10.1002/pros.2990230206 · DOI · Paper page
  9. 10.1007/s002400000111 · DOI
  10. Darnell G, 1999, Blood, 94, 781, 10.1182/blood.V94.2.781 · DOI · Paper page
  11. 10.1371/journal.pone.0036739 · DOI
  12. 10.1038/onc.2009.231 · DOI
  13. 10.1016/j.drup.2008.11.001 · DOI
  14. 10.1146/annurev.nutr.20.1.627 · DOI · Paper page
  15. 10.1111/j.1749-6632.1992.tb38657.x · DOI · Paper page
  16. 10.1128/MCB.9.10.4196 · DOI · Paper page
  17. 10.1016/j.cmet.2005.02.005 · DOI · Paper page
  18. 10.4161/auto.29394 · DOI · Paper page
  19. 10.1074/jbc.M114.599480 · DOI
  20. 10.1016/j.molcel.2008.03.003 · DOI · Paper page
  21. Hotte SJ, 2010, Curr Oncol, 17, S72, 10.3747/co.v17i0.718 · DOI · Paper page
  22. 10.1146/annurev.pharmtox.39.1.295 · DOI · Paper page
  23. 10.1016/j.bbamcr.2016.01.026 · DOI
  24. Kastan MB, 1991, Cancer Res, 51, 6304
  25. Koivisto P, 1998, Am J Pathol, 152, 1
  26. Kuo LJ, 2008, In Vivo, 22, 305
  27. 10.1016/j.bbcan.2014.01.005 · DOI
  28. Le NT, 2002, Biochim Biophys Acta, 1603, 31
  29. 10.1038/sj.leu.2402477 · DOI
  30. 10.1016/j.bcmd.2005.04.005 · DOI
  31. 10.18632/oncotarget.4349 · DOI · Paper page
  32. 10.1074/jbc.M301107200 · DOI · Paper page
  33. 10.1016/j.cell.2010.01.028 · DOI · Paper page
  34. 10.1016/j.cell.2006.01.040 · DOI · Paper page
  35. 10.1038/embor.2008.238 · DOI · Paper page
  36. 10.1126/science.1066326 · DOI · Paper page
  37. 10.1016/B978-0-12-385114-7.00004-0 · DOI · Paper page
  38. 10.1515/BC.2002.051 · DOI · Paper page
  39. 10.1016/j.bcmd.2003.08.003 · DOI · Paper page
  40. 10.1126/scitranslmed.3001127 · DOI · Paper page
  41. 10.1016/j.leukres.2014.06.005 · DOI
  42. 10.1080/15548627.2015.1091141 · DOI · Paper page
  43. 10.1002/(SICI)1096-8652(199808)58:4<299::AID-AJH9>3.0.CO;2-L · DOI · Paper page
  44. 10.1210/en.2004-0173 · DOI · Paper page
  45. 10.1074/jbc.M111.273060 · DOI
  46. 10.3322/caac.21332 · DOI · Paper page
  47. 10.1097/01.ju.0000141580.30910.57 · DOI · Paper page
  48. 10.1136/gut.2005.069021 · DOI
  49. 10.1002/pros.21383 · DOI · Paper page
  50. 10.1002/hep.24413 · DOI
  51. 10.1016/j.bbrc.2011.03.077 · DOI
  52. 10.1016/j.cell.2010.05.014 · DOI
  53. 10.1158/0008-5472.CAN-13-1224 · DOI · Paper page
  54. 10.1158/0008-5472.CAN-15-0563 · DOI · Paper page
  55. 10.1158/1541-7786.MCR-11-0065 · DOI
  56. 10.3892/ol.2015.3363 · DOI
  57. 10.1039/C5MB00663E · DOI · Paper page

Cited by

See all 47

Metadata

Authors
Deng, Z., Manz, D. H., Torti, S. V., & Torti, F. M.
Venue
Antioxidants & Redox Signaling
Published
2019-03-10
Volume
30
Issue
8
Pages
1043-1061
ISSN
  • 1523-0864 (ISSN-L)
  • 1557-7716
OpenAlex
W2765244393
Cited by
47
References
23
FWCI
2.83
Type
journal article
Language
en
Open access
green
Licence
www.liebertpub.com/nv/resources-tools/text-and-data-mining-policy/121/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.